Hepatitis Monthly

Published by: Kowsar

Substitution Rtq267h of Hepatitis B Virus Increases the Weight of Replication and Lamivudine Resistance

Bo Qin 1 , 2 , * , Bo Zhang 2 , Xiaodong Zhang 3 , Tingting He 1 , Wenying Xu 1 , Lijun Fu 1 and Chunyu Tu 1
Authors Information
1 Shaoxing Centre for Disease Control and Prevention, Shaoxing, China
2 State Key Lab of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
3 College of Life Science, Shaoxing University, Shaoxing, China
Article information
  • Hepatitis Monthly: October 01, 2013, 13 (10); e12160
  • Published Online: October 1, 2013
  • Article Type: Research Article
  • Received: May 11, 2013
  • Revised: July 7, 2013
  • Accepted: August 27, 2013
  • DOI: 10.5812/hepatmon.12160

To Cite: Qin B, Zhang B, Zhang X, He T, Xu W, et al. Substitution Rtq267h of Hepatitis B Virus Increases the Weight of Replication and Lamivudine Resistance, Hepat Mon. 2013 ; 13(10):e12160. doi: 10.5812/hepatmon.12160.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Vietheer PTK, Netter HJ, Sozzi T, Bartholomeusz A. Failure of the Lamivudine-Resistant rtM204I Hepatitis B Virus Mutants To Efficiently Support Hepatitis Delta Virus Secretion. Failure Lamivudine Resistant rtM204I Hepatitis B Virus Mutants Efficiently Support Hepatitis Delta Virus Secretion. 2005; 79(10): 6570-73
  • 2. Gao W, Hu J. Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J Virol. 2007; 81(12): 6164-74[DOI][PubMed]
  • 3. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004; 350(11): 1118-29[DOI][PubMed]
  • 4. Le Pogam S, Yuan TT, Sahu GK, Chatterjee S, Shih C. Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein. J Virol. 2000; 74(19): 9099-105[PubMed]
  • 5. Thursz M, Njie R, Lemoine M. Global eradication of hepatitis B--feasible or fallacy? . J Virol. 2012; 9(9): 492-94
  • 6. Pallier C, Castera L, Soulier A, Hezode C, Nordmann P, Dhumeaux D, et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol. 2006; 80(2): 643-53[DOI][PubMed]
  • 7. Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res. 2006; 71(2-3): 206-15[DOI][PubMed]
  • 8. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. J Virol. 2009; 137(5): 1593-608
  • 9. Lin X, Yuan ZH, Wu L, Ding JP, Wen YM. A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency. J Virol. 2001; 75(23): 11827-33
  • 10. Lanford RE, Kim YH, Lee H, Notvall L, Beames B. Mapping of the hepatitis B virus reverse transcriptase TP and RT domains by transcomplementation for nucleotide priming and by protein-protein interaction. J Virol. 1999; 73(3): 1885-93
  • 11. Qin B, Budeus B, Cao L, Wu C, Wang Y, Zhang X, et al. The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. Antiviral Res. 2013; 97(2): 93-100
  • 12. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol. 2002; 97(7): 1618-28[DOI][PubMed]
  • 13. Bo Qin TH, Zhaohui H, Guoshao P, Chunyu T, Mengji L, Xinwen C. Polymerase mutations rtN238R, rtT240Y and rtN248H of hepatitis B virus decrease susceptibility to adefovir . Chinese S Bull. 2013; 58(15): 1760-66
  • 14. Qin B, He T, Chen Z, Xu W, Pan G, Tu C. A novel method for the analysis of drug-resistant phenotypes of hepatitis B virus. Int J Mol Med. 2013; 31(4): 975-81[DOI][PubMed]
  • 15. Grunenberg R, Banik N, Kruger J. [Alanine aminotransferase (ALAT, GPT): a reevaluation of exclusion limits for blood donors]. Infusionsther Transfusionsmed. 1995; 22(3): 145-51[PubMed]
  • 16. Qiu J, Qin B, Rayner S, Wu CC, Pei RJ, Xu S, et al. Novel evidence suggests Hepatitis B virus surface proteins participate in regulation of HBV genome replication. Virologica Sinica. Vir Sinica. 2011; 26(2): 131-38
  • 17. Meng Z, Xu Y, Wu J, Tian Y, Kemper T, Bleekmann B, et al. Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA. Journal of virological methods. J Virol Me. 2008; 15(1-2): 27-33
  • 18. Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepato. 2004; 41(4): 659-66
  • 19. Cai WJ, Yin L, Zhou D, Cao WJ, Zheng WW, Sheng L, et al. Association between polymorphisms of the E-selectin gene, hepatitis B virus DNA copies and preS1 antigen in patients with chronic hepatitis B infection. Molecular medicine reports. Mol Med Rep. 2012; 6(2): 1069-74
  • 20. Zaaijer HL, van Hemert FJ, Koppelman MH, Lukashov VV. Independent evolution of overlapping polymerase and surface protein genes of hepatitis B virus. J Gen Virol. 2007; 88: 2137-43[DOI][PubMed]
  • 21. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepato. 1998; 27(6): 1670-77
  • 22. Yuen MF, Lai CL. Treatment of chronic hepatitis B. Lancet Infect Dis. 2001; 1(4): 232-41
  • 23. Preiss S, Littlejohn M, Angus P, Thompson A, Desmond P, Lewin SR, et al. Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology. 2008; 48(3): 741-9[DOI][PubMed]
  • 24. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005; 10(6): 727-34[PubMed]
  • 25. Bo Q, RongJuan P, TingTing H, ZhaoHui H, GuoShao P, ChunYu T, et al. Polymerase mutations rtN238R, rtT240Y and rtN248H of hepatitis B virus decrease susceptibility to adefovir. Chinese Science Bulletin. Chinese S Bull. 2013; 58(15): 1760-66
  • 26. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antiviral Ther. 2004; 9(3): 353-66
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments